Objective: Folates provide one-carbon units for nucleotide synthesis and methylation reactions.
INTRODUCTION
Folate, an essential vitamin for synthesis, repair and methylation of DNA, helps to maintain genome integrity. Methylenetetrahydrofolate reductase (MTHFR) may play a key role in regulating distribution of one-carbon moieties between nucleotide synthesis and methylation reactions (Figure 1) . MTHFR catalyzes the irreversible reduction of 5,10-methylenetetrahydrofolate (5,10-methyleneTHF) to 5-methyltetrahydrofolate (5-methylTHF).
The substrate of MTHFR provides carbon units for conversion of dUMP to dTMP by thymidylate synthase (TS), or is converted to 10-formyltetrahydrofolate (10-formylTHF) for purine synthesis. The product of MTHFR serves as the methyl donor for remethylation of homocysteine to methionine; methionine is converted to S-adenosylmethionine (SAM) for use in numerous methylation reactions. S-adenosylhomocysteine (SAH), the by-product of methylation reactions, is subsequently hydrolyzed, thus regenerating homocysteine, a potentially cytotoxic amino acid. In addition to remethylation, homocysteine may undergo transsulfuration to generate cysteine and glutathione.
Homozygosity for a polymorphism in MTHFR (677CT) results in the production of a thermolabile enzyme with reduced activity [1] . Individuals with mild MTHFR deficiency, which affects 10 -15% of many Caucasian populations, have lower levels of methylTHF [2] , elevated plasma Hcy [1] and global DNA hypomethylation [3] . 677TT individuals are also at higher risk for neural tube defects, vascular disease and pregnancy complications [4] and are at lower risk for certain forms of leukemia and colorectal cancer [5, 6] . Furthermore, since mild MTHFR deficiency disrupts the flux of one-carbon moieties, there is recent interest in examining the ways in which 677TT individuals respond to drugs that target folate metabolism, such as methotrexate.
Methotrexate (MTX) is widely used in treatment of leukemia, solid tumors, and rheumatoid arthritis. It is an inhibitor of dihydrofolate reductase (DHFR), the enzyme required to maintain the active tetrahydrofolate (THF) pool. As a consequence of this inhibition, 5,10-methyleneTHF and 10-formylTHF, the carbon donors in biosynthesis of thymidylate and purines, respectively, are depleted resulting in inhibition of DNA and RNA synthesis, cell cycle arrest and apoptosis [7] . 5-MethylTHF pools are also affected by MTX and their depletion results in hyperhomocysteinemia and DNA hypomethylation [8, 9] .
Response to MTX can be influenced by polymorphisms in genes encoding folatedependent enzymes [10] . The most common MTX side effect is myelosuppression, characterized by anemia (reduced hematocrit, hemoglobin and number of red blood cells), leucopoenia (reduced number of white blood cells) and thrombocytopenia (reduced number of platelets) [11] . Other MTX-related complications include neurotoxicity, renal dysfunction, hepatotoxicity, and gastrointestinal toxicity [12] . Recent studies have suggested an association between the MTHFR polymorphism and increased MTX toxicity or decreased efficacy [11, [13] [14] [15] [16] . Among bone marrow transplant patients treated with MTX, 677TT patients had a higher risk of oral mucositis and delayed platelet recovery compared to 677CC patients [11] . 677TT patients experienced severe myelotoxicity following cyclophosphamide, MTX, and 5-fluorouracil treatment for early breast cancer [13] , and this genotype group with acute lymphoblastic leukemia or acute promyelocytic leukemia was more likely to display myelosuppression and hepatotoxicity following MTX treatment [17] .
In this study, we investigated the effects of altered MTHFR activity on MTX response in vivo, using mouse models. In earlier work, we had generated Mthfr-deficient mice and showed that Mthfr −/− and Mthfr +/− mice have altered distribution of folates, hyperhomocysteinemia and decreased DNA methylation [18, 19] ; these findings are similar to those observed in 677TT
individuals. Since MTX interferes with DNA synthesis and increases homocysteine levels, we hypothesized that Mthfr deficiency might enhance MTX-dependent cytotoxicity on hematopoietic cells and enhance the increase in homocysteine. To further test the impact of MTHFR expression on MTX response, we generated an MTHFR-overexpressing transgenic mouse line (MTHFR-Tg). We hypothesized that, in response to MTX, MTHFR-Tg mice would have reduced availability of 5,10-methyleneTHF for DNA synthesis and therefore an adverse hematopoietic profile. We found that MTX-treated Mthfr-deficient and MTHFR-Tg mice were both adversely affected in terms of proliferation of the hematopoietic system, compared to their wild-type littermates, although they responded differently with respect to homocysteine elevation and nephrotoxicity.
5

MATERIALS AND METHODS
Methotrexate response
Mice
Experimentation received approval from the Animal Care Committee of the Montreal
Children's Hospital according to the recommendations of the Canadian Council on Animal Care.
Mice were fed standard mouse chow (Laboratory diet 5001, Agribrands Purina).
Adult male mice were injected intraperitoneally once every three days for two weeks (four injections total) with either saline or MTX (Faulding). The doses of MTX , either 10 mg/kg (LD10) or 20 mg/kg (LD20), have been demonstrated to produce toxicity without death [20] . Weight loss and general appearance were evaluated after each injection. Twenty-four hours after the last injection, mice were sacrificed for cardiac blood and tissues.
The first study examined the effect of Mthfr deficiency on response to MTX. Adult male Mthfr −/− , Mthfr +/− and Mthfr +/+ mice were used; these mice were the result of 15 generations of backcrossing to C57Bl/6 from BALB/c, the original background strain [18] . C57Bl/6 Mthfr −/− mice have a higher survival rate compared with BALB/c Mthfr −/− mice (unpublished data).
The second study examined the effect of MTHFR overexpression on response to MTX.
MTHFR-Tg, generated as described below, and wild-type littermates were the result of at least 6 generations backcrossing to C57Bl/6 from their original mixed background (129/Sv and C57Bl/6).
Hematological parameters
Cardiac blood was collected in potassium-EDTA tubes. Complete blood cell counts were obtained through the Animal Resource Center of McGill University.
Measurements of plasma total homocysteine (tHcy)
Cardiac blood was collected in potassium-EDTA tubes. Plasma was collected after centrifugation (6000xg, 6 minutes, 4°C) and stored at -70°C. Measurements were performed by HPLC [21] .
Serum aspartate aminotransferase and blood urea nitrogen levels
Cardiac blood was collected in serum gel tubes. Serum was collected after centrifugation (4000xg,10 minutes, room temperature) and analyzed on the day of collection by a clinical chemistry automatic analyzer at the Animal Resource Center of McGill University.
Evaluation of nucleotide pools
6
Free deoxyribonucleotides were separated by HPLC as previously described [22] 
MTHFR-overexpressing transgenic mice
Generation
An HPRT targeting vector was constructed in which a MTHFR cDNA regulated by the CMV promoter was inserted by Gateway technology (Invitrogen) [23] . The parent plasmid,
pIRES-MTHFR (MTHFR coding sequence inserted into the pIRES vector), was digested with
NsiI and BsrGI into 2 segments: 6 kb (mouse CMV promoter, MTHFR cDNA, polyadenylation site and ampicillin resistance) and 1.3 kb (non-MTHFR sequences). The 6 kb fragment was selfligated and transferred into E. coli Top 10 F'. Positive ampicillin-resistant colonies were selected by restriction digestion and sequencing of junction areas. A positive clone, designated pCMVMR, was digested with NruI and XhoI to isolate a 4.9 kb segment (CMV promoter, MTHFR cDNA and polyadenylation site), which was ligated into pENTR 1A (Gateway entry vector). pENTR1A carries the attL1 and attL2 recombination sites for efficient recombination with a Gateway-based Hprt targeting vector which carries attR1 and attR2 recombination sites [23] . The ligation product was transformed into E. coli Top 10 F'. Positive kanamycin-resistant colonies were selected by restriction digestion and sequencing of junction areas. The resulting construct was pENTRMR. Site-specific recombination of pENTRMR with the HPRT destination vector [23] , at the att sites, generated the final construct pHPRTMR, which was transferred into E. coli Top 10 F'. Ampicillin-resistant colonies were selected and analyzed by restriction digestion and sequencing of junction areas. To increase homologous recombination efficiency, pHPRTMR was linearized with PvuI before electroporation into Hprt-ES cells. overexpression by enzymatic assays [24] . Three of these positive ES clones were injected into C57Bl/6 blastocysts and two chimeric male mice derived from one clone successfully transmitted the MTHFR transgene to the next generation (germline female mice). Germline female mice were mated with male C57Bl/6 mice and offspring were backcrossed onto the C57Bl/6 background for at least 5 generations.
PCR-based genotyping
For identification of mice with a transgene, mice were genotyped by PCR using a human MTHFR cDNA [25] Figure S1A , right panel.
Southern blotting
Genomic DNA was digested with DraIII and ScaI, ApaLI and ScaI, or PshAI, separated by agarose electrophoresis, and blotted. Blots were probed with an 847 bp DIG-labeled DNA segment specific for a portion of the CMV promoter and MTHFR exons 1 and 2. The DNA probe was generated using primers 5'-CCT ACT TGG CAG TAC ATC TAC GTA t -3' and 5'-GCT TAG CTT TGT GCA GAT GGC CC-3', with the PCR DIG Probe synthesis kit (Roche).
Images were generated by exposure to lumi-film chemiluminescent detection film (Roche) ( Figure S1B ).
RT-PCR, Western blotting and MTHFR enzyme activity assays
After RNA isolation using the Trizol procedure (Invitrogen) and treatment with DNase (Invitrogen), RT was performed with SuperScript II Reverse Transcriptase (Invitrogen) and RT-PCR was performed using primers in exon 2 and exon 5; mouse Gapdh served as the internal control [18] . Intensity of the Mthfr band relative to Gapdh was used to estimate mRNA levels.
Protein extracts from cells and tissues were prepared as described [18] . For Western blotting, 50-100 µg protein were run on SDS-polyacrylamide gels. Proteins were transferred to nitrocellulose membranes at 70 V, 2 hours at 4°C. Nonspecific binding sites were blocked with 2% skim milk in Tris-buffered saline/Tween buffer overnight at 4°C. Blots were incubated with rabbit antiserum against purified MTHFR [1] or β-Actin (control). Intensity of the MTHFR band relative to β-Actin was used to estimate protein levels. An activity assay, which assays MTHFR in the physiologically reverse direction, was performed using radiolabeled 14 C-5-methylTHF monoglutamate as substrate and menadione as electron acceptor, as previously described [24] .
Evaluation of global DNA methylation
HPLC with UV detection [27] or TLC (Thin Layer Chromatography) [28] was used to calculate the ratio of methylated cytosines/ (methylated cytosines + unmethylated cytosines). For HPLC, 10 µg of RNA-free genomic DNA was treated with nuclease P1 and calf intestinal alkaline phosphatase (CIAP). Bases were separated on a column using buffers containing 0.01M TLC was performed as previously described [28] . 5 µg of RNA-free genomic DNA was 
Measurement of folate-related metabolites
Levels of SAM, SAM/SAH, adenosine, methionine, homocysteine, GSH, cysteinylglycine and cysteine in liver, brain and duodenum were measured by HPLC using electrochemical (coulometric) detection [29] .
Measurement of folate derivatives
Levels of 5,10-methyleneTHF, 5-methylTHF, 10-formylTHF, dihydrofolate and total folate in plasma, liver, brain and duodenum were measured by a ternary complex assay [30] .
Statistical analysis
Two-factor analysis of variance (ANOVA) and independent-sample t-tests were performed using SPSS for WINDOWS software, version 11.0. P-values <0.05 were considered significant.
RESULTS
Effects of MTHFR deficiency on MTX treatment
Plasma thiols
Mice treated with MTX (10 mg/kg) had higher plasma homocysteine and homocysteine/cysteine ratios, compared to mice injected with saline (Figure 2A, 2C) . Mthfr
and Mthfr −/− mice had elevated homocysteine compared to Mthfr +/+ mice, as previously described [18] . A genotype effect was also evident in cysteine levels, specifically between Mthfr −/− and Mthfr +/+ in both treatment groups ( Figure 2B ).
Hematological parameters
This experiment was carried out using 10 mg/kg and 20 mg/kg MTX, with similar trends.
However, genotype differences were more pronounced at 20 mg/kg. Hematocrit, hemoglobin and RBC number in MTX-treated mice were significantly lower compared to those in saline- We also performed Southern blotting of DNA from homozygous transgenic female mice to confirm that the expected recombination event had occurred at Hprt and to identify positive animals in subsequent generations ( Figure S1, B and C) . Bands of the expected sizes were observed for transgenic animals and not in wild-type mice.
Confirmation of overexpression
Germline female mice were mated with C57Bl/6 mice and in male progeny, MTHFR overexpression was confirmed in various tissues ( Figure S2 ). All studies were performed on male mice, to avoid confounding by X inactivation, since the transgene is inserted into the X- 
Metabolite levels
Measurements of reduced folate pools (Table 1 ) and of relevant tissue metabolites ( has low quantities of total folate compared to liver and intestine, also did not display any genotype-specific differences. However, in liver and duodenum, MTHFR-Tg mice had significantly lower levels of 10-formylTHF. Evaluation of metabolites in the homocysteine remethylation and transsulfuration pathways revealed some genotype-specific and tissue-specific differences ( Table 2) . MTHFR-Tg mice had an increase of methionine in brain, an increase of glutathione in liver, and a decrease of cysteine in duodenum.
The decrease in 10-formylTHF is consistent with enhanced conversion of nonmethylTHF to methylTHF by MTHFR. Increased availability of methylTHF would drive methionine synthesis by homocysteine remethylation, as shown by the significant increase of methionine in brain and a nonsignificant increase in liver.
MTHFR-Tg and wild-type littermates were also examined for deoxyribonucleotide pools (dUTP/dTTP ratios) in liver, duodenum and brain. Global DNA methylation was assessed in liver, duodenum and brain by 2 methods: HPLC and TLC. There were no significant genotype differences in these parameters (data not shown, n= 5 per genotype).
Effects of MTHFR overexpression on MTX treatment
Plasma thiols
Mice treated with MTX (10 mg/kg) had higher plasma homocysteine compared to mice injected with saline ( Figure 6 ). However, mice with MTHFR overexpression had lower plasma homocysteine levels and lower homocysteine/cysteine ratios following MTX treatment compared to their MTX-treated wild-type littermates.
Hematological parameters
Hematocrit, hemoglobin and RBC number in MTX (10 mg/kg or 20 mg/kg)-treated mice were significantly lower compared to those in saline-treated mice (Figure 7 , data shown for MTX 10 mg/kg). Compared to saline-treated mice, these three parameters were significantly reduced in MTX-treated MTHFR-Tg mice, but unaffected in MTX-treated wild-type mice.
Furthermore, in MTX-treated mice, MTHFR overexpression was associated with lower hematocrit, hemoglobin and RBC number compared to wild-type littermates.
dUTP/dTTP ratios
MTX treatment significantly increased dUTP/dTTP ratios in spleen of both genotype groups, suggesting that there was decreased folate-dependent conversion of dUMP to dTMP due to the drug (Figure 8) . This observation is similar to the trend discussed above for MTX-treated
Mthfr-deficient mice. However, these ratios were significantly higher in MTHFR-Tg mice compared to wild-type littermates, in both the saline-and MTX-treated groups, suggesting that MTHFR overexpression also compromises the conversion of dUMP to dTMP. This observation is consistent with enhanced conversion of 5,10-methyleneTHF to 5-methylTHF through MTHFR overexpression, which decreases availability of 5,10-methyleneTHF for thymidine synthesis.
Toxicity
There were no significant treatment or genotype differences in serum BUN or AST levels in the experiments on MTHFR-Tg mice and their wild-type littermates (data not shown).
DISCUSSION
Genetic disruptions in folate metabolism may influence the efficacy or toxicity of chemotherapeutics that target enzymes in folate metabolism. To understand the regulation of one-carbon metabolism and the interaction between MTHFR activity and MTX, we used a wellcharacterized mouse model deficient in MTHFR (Mthfr −/− and Mthfr +/− ) and generated a new model that overexpresses MTHFR (MTHFR-Tg).
By inhibiting DHFR, MTX limits the reduction of dihydrofolate to THF, thereby disrupting all THF-dependent reactions [7] . Two of these reactions, thymidine and purine synthesis, are reduced due to decreased availability of 5,10-methyleneTHF and 10-formylTHF, We have previously reported that Mthfr −/− mice have lower plasma total folate levels (25% of wild-type) and a lower proportion of 5-methylTHF in plasma, liver and brain [19] .
An alternate mechanism for enhanced myelosuppression in Mthfr-deficient mice is increased apoptosis of hematopoietic cells. Apoptosis may be triggered by the high circulating homocysteine levels in Mthfr −/− and Mthfr +/− mice. Several studies have demonstrated a proapoptotic effect of homocysteine in cortical neurons and cultured lymphocytes, possibly through an increase in oxidative stress [31, 32] and we have directly demonstrated increased apoptosis in brain of Mthfr −/− mice [33] . Furthermore, a metabolite of Hcy, Hcy thiolactone, has been shown to be elevated in hyperhomocysteinemic humans and mice [34] , and may be more efficient than Hcy in promoting apoptosis [35, 36] . Studies are underway to examine interaction between MTX and MTHFR deficiency in promoting apoptosis in mice.
By reducing total folate, MTX inhibits methyleneTHF-dependent thymidine synthesis. Our finding of increased splenic dUTP/dTTP ratios following MTX treatment in wild-type mice and in MTHFR-Tg mice is consistent with this argument. A reduction in MTHFR activity might be expected to counteract this effect since MTHFR deficiency increases nonmethylfolate, which would include methyleneTHF. Nucleotide ratios tended to decrease in Mthfr-deficient mice, albeit nonsignificantly, but this imbalance did not seem to play a major role in hematopoiesis since Mthfr-deficient mice were more dramatically affected than wild-type animals following MTX treatment.
Toxicity is a major concern in the use of MTX. Nephrotoxicity (assessed by BUN levels)
was observed in all groups following MTX treatment and was particularly marked in Mthfr patients [30, 37] .
To further explore the role of MTHFR, we created MTHFR-overexpressing mice.
Overexpression was demonstrated in several tissues, with 2-to 3-fold increases in mRNA, protein and enzyme activity. The consistent increases in all three parameters suggest that there was little or no post-transcriptional regulation of MTHFR. Enhanced MTHFR expression should lead to increased 5-methylTHF formation at the expense of 5,10-methyleneTHF and other nonmethylTHF derivatives, such as 10-formylTHF (which is synthesized from 5,10-methyleneTHF). Our observed decreases in hepatic and intestinal 10-formylTHF in MTHFR-Tg mice are consistent with this altered distribution pattern. As mentioned above, the folate redistribution in Mthfr-deficient mice [19] is in the reverse direction to that seen in these MTHFR-Tg animals. Together, our data confirm the important role that MTHFR plays in maintaining the balance between folates destined for nucleotide synthesis and those destined for methionine synthesis.
Methionine is formed through homocysteine remethylation, a process which utilizes 5-methylTHF. Enhanced homocysteine remethylation was observed in the MTHFR-Tg mice, as demonstrated by elevated brain methionine. Although methionine elevations were not observed in liver or intestine, there was evidence of enhanced homocysteine transsulfuration to glutathione in liver, a process which is regulated by SAM. Since SAM activates cystathionine-β-synthase, the first enzyme in the transsulfuration pathway [38] , increased production of methionine and SAM in these tissues should enhance homocysteine transsulfuration to generate cysteine and glutathione. Rodents preferentially convert cysteine to glutathione; methionine-enriched diets in mice resulted in increased plasma glutathione levels without changes in cysteine [39] . The observations in that study are consistent with our observation of increased glutathione in liver.
The decrease in cysteine in the intestine is consistent with enhanced conversion of cysteine to glutathione although we did not observe a change in glutathione levels in this tissue. Brain does not have an active transsulfuration pathway [40] , as indicated by the relatively low baseline levels of cysteine in brain compared to other tissues, and the absence of a change in transsulfuration metabolites in the transgenic mice. In our earlier study of mice with decreased MTHFR expression (Mthfr −/− and Mthfr +/− ), we observed the reverse pattern i.e., a decrease in methionine and glutathione with an increase in cysteine in liver [41] .
We did not observe significant decreases in 5,10-methyleneTHF levels in transgenic mice. Nonetheless, there were two manifestations of methyleneTHF reductions: the decrease in 10-formylTHF, as mentioned above, and the increase in the dUTP/dTTP ratio in spleen, indicating compromised activity of thymidylate synthase presumably due to the decrease in its substrate 5,10-methyleneTHF. The altered nucleotide ratios in spleen of transgenic mice were observed in untreated and MTX-treated mice.
MTX treatment resulted in the expected decreases in several hematopoietic parameters (hematocrit, hemoglobin and RBC number) in both MTHFR-Tg and wild-type mice. MTHFR-Tg mice responded similarly to Mthfr −/− mice, with greater reductions in these parameters compared to wild-type littermates. This finding, as well as the pronounced MTX-induced dUTP/dTTP ratio increase, may be due to the inherent reduction in nonmethylTHF in MTHFRoverexpressing mice. These decreases in thymidine synthesis and in proliferation of cells in transgenic mice suggest that increased MTHFR expression may enhance chemosensitivity to MTX.
A major side effect of MTX, hyperhomocysteinemia, is a risk factor for coronary artery disease, stroke and neurologic impairment [42, 43] . In our study, MTHFR overexpression was protective against MTX-induced homocysteine increases; MTX treatment increased plasma homocysteine levels in wild-type mice but not in MTHFR-Tg littermates. In addition, MTHFRTg mice did not have elevations in markers of nephrotoxicity or hepatotoxicity, in contrast to our observations in Mthfr −/− mice.
There were no differences in homocysteine levels or in hematopoietic parameters between untreated wild-type and transgenic mice. This finding suggests that the 2-to 3-fold increase in MTHFR activity alone was not enough to disturb these functions. However, the combined stress of genetic disruption and drug treatment led to more significant effects on homocysteine remethylation and to a greater inhibition of proliferation. In summary, an increase in MTHFR expression during MTX treatment may enhance chemosensitivity of hematopoietic cells to MTX, through an increase in dUTP/dTTP ratios, without enhancing nephrotoxicity or hyperhomocysteinemia. A decrease in MTHFR expression during MTX treatment has similar effects on chemosensitivity but is associated with enhanced toxicity and hyperhomocysteinemia.
The enhanced chemosensitivity in this situation may be due to homocysteine-mediated apoptosis.
There is significant inter-patient variability in response to MTX treatment, and MTX toxicity is often the reason for discontinuation of therapy. Pharmacogenetic analysis of polymorphisms in folate-metabolizing enzymes may provide a useful tool to predict MTX efficacy or toxicity and thereby maximize the benefit : risk ratio. Our studies illustrate the critical role of MTHFR in MTX chemosensitivity and the importance of pharmacogenetic testing for the MTHFR polymorphism and possibly other polymorphisms in folate metabolism. 25.5
13.0 Methionine levels in brain were increased, glutathione levels in liver were increased, and cysteine levels in duodenum were decreased in Tg compared to Wt littermates.
SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine; GSH, Glutathione; CysGly, Cysteinylglycine. *, # P<0.05, two-factor ANOVA for treatment and genotype, respectively. MTX-treated mice had significantly higher plasma Hcy and Hcy/Cys ratios compared to saline-treated mice.
There was a significant difference in plasma Hcy and cysteine levels, and Hcy/Cys ratios among Autoradiographs from liver, kidney and heart were generated from one gel, and autoradiographs from intestine and brain were generated from another gel. (C) The MTHFR enzyme assay, which assays MTHFR in the physiologically reverse direction, was performed using radiolabeled 5-methylTHF monoglutamate as substrate and menadione as electron acceptor. Specific MTHFR activity was calculated for each sample; values are mean of 3 -5 mice ± S.E.M. Filled bars depict values for wild-type mice; unfilled bars, Tg littermates.
